|
|
|
|
|
View Full Text (PDF)
|
|
Biotechnology in Hong Kong Volume IV New 2020 Edition
Edited by Albert Wai-Kit Chan, Ph.D., J.D.
Published by USCIPI
USCIPI is proud to present Biotechnology in Hong Kong (Volume IV)! Once again, we've gathered over 20 authors, experts in multiple disciplines, to share their perspectives and help educate on the developments in biotechnology in Hong Kong and China (by extension). As the current political and economic landscapes continually change, it would not be surprising if these fluctuations may have a negative effect on innovation and technology. However, though some may see these as troubling times, these articles reflect the enduring spirit of exploration and creation of the scientists, educators, and professionals that persevere with their amazing work. This collection of articles serves as an update of biotechnology in Hong Kong, which is still very much so a gateway for business in China. With the US and China as world leaders in innovation, there is so much potential for excellence, collaboration, and great inventions that would benefit mankind.
|
|
View Full Text (PDF)
|
|
Biotechnology in Hong Kong Volume III
Edited by Albert Wai-Kit Chan, Ph.D., J.D.
Published by USCIPI
We at the United States-China Intellectual Property Institute Inc. (USCIPI) are pleased present Biotechnology in Hong Kong (Volume III), a continuation of this series where experts in multiple disciplines share their thoughts on the topic of Biotechnology and its role in Hong Kong. As a reflection of the Chinese market's sustained growth these past few years, other cities like Shenzhen (being considered the new Silicon Valley) have emerged as important hubs. This compilation of papers serves as an update of biotechnology in Hong Kong, which continues to be a major hub for business in China. According to the World Intellectual property Organization, China leads the world on the number of patent applications filings. This a great time for biotechnology companies. We have gathered over 20 authors, experts from Hong Kong and abroad, to share their perspective of biotechnology and how it fits in Hong Kong and China.
|
|
View Full Text (PDF)
|
|
Innovation Value Chain of Chinese Pharmaceuticals
Edited by
Yitao Wang, M.D.
Yuanjia Hu, Ph.D.
Albert Wai-Kit Chan, Ph.D., J.D.
Published by USCIPI
Pharmaceutical innovation, referred to in this book as the whole process of bringing a new drug to market, involves a series of research stages and regulatory approvals which usually take about 10-15 years for a new drug. This book re-examines pharmaceutical innovation in China from the viewpoint of the innovation value chain by sequentially scanning different sections in the whole process of drug innovation including idea generation indicated by academic articles, basic research, and applied development measured by ongoing projects, technology flow captured by patent citations, technology valuation and transfer, product registration, and the launch of new drugs. Each chapter is an independent research work which may either involve a specific therapeutic area or generally focus on a stage, but they can structurally be linked within the whole chain. Most of them are empirical studies based on substantial data and qualitative analysis.
|
|
View Full Text (PDF)
|
|
知识产权商业化理论与实践
Intellectual Property Commercialization Theory and Practice
Edited by Albert Wai-Kit Chan and Yao Deng
Published by USCIPI
《知識產權商業化理論與實踐研究》,是一本探討知識產權商業化的基本概念、內容、模式以及實務中一些具體個案和問題的專業著作。本書由來自美國、中國大陸、香港、澳門、臺灣等國家和地區的各界專家共同參與撰寫。他們中有從事教學研究的大学教授、學者,從事知識產權運營的專業人士,還有在知識產權法領域具有資深造詣和豐富經驗的法官和律師。作者既研究探討基本理論,也總結交流實踐體會,并對相關商業案例和訴訟案例进行了介紹和評析。本書編寫時不僅考慮了整體結構和章節分類,同時保持了各章節的相對獨立性,进而勾勒出知識產權商業化的基本理論體系和實踐現狀,同時也讓讀者瞭解到每位作者的不同觀點和主張。
全書共分為七章:第一章,知識產權商業化的基本概念和內容;第二章,知識產權商業化的路徑和市場模式;第三章,專利的國際商業運用;第四章,專利價值與評估;第五章,知識產權融資與保險;第六章,知識產權管理與商業化;第七章,知識產權商業化中的法律問題。
The book "Intellectual Property (IP) Commercialization Theory and Practice" studies the basic concept, scope, and model of IP commercialization, together with specific cases and challenges in practice. The book is jointly written by a number of experts in various fields from the United States, China (Mainland), Hong Kong, Macau, Taiwan and other countries/districts. The authors include university faculties/scholars, IP-management professionals, and judges and attorneys with solid knowledge and extensive experience in IP field. Here, the authors not only explore and discuss the basic theories and common practice but also review and study the actual cases in IP commercialization and litigation. The book is compiled based upon the overall structure and chapter classification and yet also aimed at preserving the independence of each chapter. It outlines the fundamental theoretic system and current status of IP practice, and allows readers to understand the different perspective of each author.
The book is divided into seven chapters: Chapter I, Basics and Scopes of IP Commercialization; Chapter II, Approaches and Business models of IP Commercialization; Chapter III, Use of Patents in International Business; Chapter IV, Value and Valuation of Patents; Chapter V, IP Financing and Insurance; Chapter VI, IP Management and Commercialization; and Chapter VII, Legal Issues in IP Commercialization.
|
|
View Full Text (PDF)
|
|
Biotechnology in Hong Kong Volume II
Edited by Albert Wai-Kit Chan, Ph.D., J.D.
Published by USCIPI
Over 15 years ago, at a time when Hong Kong was entering a new era as a Special Administrative Region of China and its future was uncertain, we at the United States-China Intellectual Property Institute Inc. (USCIPI) gathered experts in multiple disciplines to share their thoughts on the topic of Biotechnology and its role in Hong Kong. These past few years has seen the Chinese market growing by leaps and bounds. Soon, the People�s Republic of China will be #1 in funding for R&D, surpassing the US. With Hong Kong serving as one of its major gateways, a careful study at this topic could not be timelier. We are pleased to present Biotechnology in Hong Kong (Volume II) for a fresh look and new perspectives from key figures in this pivotal field.
|
|
View Full Text (PDF)
|
|
Biotechnology in Hong Kong
Edited by Albert Wai-Kit Chan, Ph.D., J.D.
Published by USCIPI
The summer of 1997 saw the handover of Hong Kong to China to become a Special Administrative Region. At the time, the social, political and economic future of Hong Kong was uncertain. In particular, there was much speculation regarding biotechnology and how it could be sustained and grown. Here is a collection of over 30 voices ranging from inventors, scholars, and entrepreneurs offering their thoughts on the state of biotechnology, the roles of the private sector and government, and the future of biotechnology in Hong Kong. The perspectives and observations are compelling and some concepts seem to be applicable even today.
|
|
|
|